Clinical Pipeline
Immuteps Active Oncology & Autoimmune Disease Pipeline
Oncology
Eftilagimod Alfa (LAG-3lg or IMP321), APC activating Soluble LAG-3 Protein
Preclinical
Phase I
Phase II
Phase III
Collaborators
TACTI-004 (IO-IO Combo)1
First Line Non-Small Cell Lung Cancer (1L NSCLC)
Clinical Collaborators
Immutep conducts this clinical trial and has a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Kenilworth, NJ, USA).
TACTI-003 (IO-IO Combo)1
First Line Head and Neck Cancer (1L HNSCC)
Clinical Collaborators
Immutep conducts this clinical trial and has a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Kenilworth, NJ, USA).
INSIGHT-003 (IO-IO-Chemo) 2
1L Non-Squamous NSCLC
Clinical Collaborators
INSIGHT is an investigator-initiated study conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt.
INSIGHT-005 (IO-IO Combo) 2, 3
Metastatic Urothelial Cancer
Clinical Collaborators
INSIGHT is an investigator-initiated study conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. Immutep has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany for INSIGHT-005. Under the agreement, Immutep and Merck KGaA, Darmstadt, Germany jointly fund the study.
EFTISARC-NEO (IO-IO-Radiotherapy) 2
Soft Tissue Sarcoma
Clinical Collaborators
EFTISARC-NEO is an investigator-initiated open label Phase II clinical trial conducted by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland.
AIPAC-003 (Chemo-IO Combo)
Metastatic HER2-neg/low Breast Cancer & Triple-Negative Breast Cancer
Clinical Collaborators
EOC 202 (Chemo-IO Combo)4, 5
Metastatic Breast Cancer
Clinical Collaborators
Immutep retains global rights to efti ex-mainland China, Hong Kong S.A.R, Macao S.A.R. and Taiwan, where EOC Pharma has licensed efti rights; Immutep may receive milestones and royalty payments from EOC Pharma.
Autoimmune Diseases
Preclinical
Phase I
Phase II
Phase III
IMP731 Ulcerative colitis5
Depleting LAG-3 Antibody
Clinical Collaborators
IMP731 Psoriasis5
Depleting LAG-3 Antibody
Clinical Collaborators
IMP761 Healthy Volunteers
Agonist LAG-3 Antibody
Clinical Collaborators
Out-Licensed Pipeline*
Preclinical
Phase I
Phase II
Phase III
IO-IO Combo: Solid Tumors + Blood Cancer5
Clinical Collaborators
Novartis has licensed global rights and funds all development costs; Immutep may receive milestone and royalty payments.
Chemo-IO Combo: Triple Negative Breast Cancer5
Clinical Collaborators
Novartis has licensed global rights and funds all development costs; Immutep may receive milestone and royalty payments.
IO-IO-Small Molecule Combo: Melanoma5
Clinical Collaborators
Novartis has licensed global rights and funds all development costs; Immutep may receive milestone and royalty payments.
IO-IO Combo: Solid Tumors5
Clinical Collaborators
Novartis has licensed global rights and funds all development costs; Immutep may receive milestone and royalty payments.
Chemo-IO-Small Molecule Combo: Triple Negative Breast Cancer5
Clinical Collaborators
Novartis has licensed global rights and funds all development costs; Immutep may receive milestone and royalty payments.
Immutep’s Controlled and Out-licensed Pipeline*
* Information in pipeline chart current as of July 2025
(1) In combination with KEYTRUDA® (pembrolizumab)
(2) An Investigator Initiated Trial (“IIT”) that Immutep has no control over
(3) In combination with BAVENCIO® (avelumab)
(4) EOC Pharma is the sponsor of the EOC 202 clinical trial
(5) Completed clinical trial
